Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers
- Registration Number
- NCT04652297
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Brief Summary
The primary objective of this study is to assess the safety and tolerability of single and multiple oral administration of HS-10356 in healthy volunteers.
- Detailed Description
This is a phase I, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10356 oral formulation in Chinese healthy adult volunteers.
Approximately five sequential dose panels (single oral doses of 2,6,15,30,45mg HS-10356) will be evaluated in SAD. To protect the safety of volunteers, two sentinel volunteers were first enrolled in the first dose panel (2mg panel) and randomly assigned to HS-10356 or placebo in a 1:1 ratio. After the sentinel volunteers were given the dose for at least 24 hours and confirmed that they were safe, the remaining 6 volunteers were randomly assigned to HS-10356 or placebo in a ratio of 5:1. For the follow-up panels of SAD, volunteers were randomly assigned to either the experimental group or the placebo group (6 cases in HS-10356 and 2 cases in placebo) in a 3:1 ratio using block randomization method. Approximately three sequential dose panels (14 consecutive days for respectively daily oral doses of 6,15,30mg HS-10356, QD) will be evaluated in MAD. Volunteers were randomly assigned to either the experimental group or the placebo group (9 cases in the HS-10356 and 3 cases in the placebo) in a ratio of 3:1 using block randomization method. Each subject will receive only one regimen in this study. Safety data up to Day12 (±2) in SAD and up to Day25 (±2) in MAD will be reviewed prior to dose escalation. Cohorts of SAD and MAD will be added or removed depending on the assessment results of SRC.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 76
Not provided
- Pregnant and breastfeeding female.
- Volunteers with a history of cardiovascular, respiratory, liver, kidney, digestive tract, mental, neurological, hematological, metabolic and other systemic diseases, who are not suitable to participate in this study as assessed by the investigator.
- The results of vital signs, physical examination, laboratory examination and 12-lead ECG during screening were abnormal with clinical significance.
- Major surgery was performed within 3 months prior to the screening or surgery was planned during the study.
- Severe infections, such as cellulitis, pneumonia, sepsis, have occurred or are present in the 30 days prior to screening.
- ALT, AST, ALP or bilirubin were higher than the upper limit of normal.
- Creatinine clearance < 90mL/min at screening (Cockcroft-Gault method), as follows:
(140-age in years)×weight (kg)/72×serum creatinine（mg/dL）×(Female×0.85)；
8.Hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), human immunodeficiency virus antibody (HIVAb) or syphilis antibody is positive.
9.Volunteers had a history of drug dependence or abuse.
10.A heavy smoker or smokers who smoked 5 or more cigarettes per day for 3 months prior to screening or tested positive for nicotine during screening.
11.A history of alcohol abuse or a single consumption of more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 150 mL of wine) in the nearly two weeks prior to screening or a positive breath test for alcohol at screening.
12.Participate in clinical trials of any drug or medical device within 3 months prior to screening.
13.Blood donation or blood loss ≥ 400mL within 3 months prior to screening, or blood transfusion received; Blood donation or blood loss ≥ 200mL within 1 month before screening.
14.Volunteers received systemic steroid, immunomodulator, or chemotherapy in the 3 months prior to screening，or likely to be treated with these drugs such as corticosteroids, immunoglobulin, and other immune or cytokine therapy during the study period.
15.Gastrointestinal ulcer, gastroesophageal reflux disease, or other severe symptoms of excess gastric acid secretion.
16.Medical or surgical treatment that permanently alters oral drug absorption and excretion, such as Gastric or intestinal surgery. Cholecystectomy, appendectomy and hernia repair are excluded.
17.Potent CYP3A4 inhibitors and potent CYP3A4 inducers was used within 28 days before administration.
18.Any medication taken within 2 weeks of administration, including prescription, over-the-counter, and herbal medicines.
19.Grapefruit juice, grapefruit and Seville orange juice were consumed in the 2 weeks prior to administration.
20.Diet or dietary treatment or significant change in dietary habits within 30 days prior to administration for whatever reason.
21.Volunteers who have difficulty swallowing solid tablets or capsule. 22.Volunteers with difficulty in blood collection, unable to tolerate multiple venous blood collection and any blood collection contraindications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description HS-10356 single dose HS-10356 Single oral dose of HS-10356 ascending dose placebo single dose Placebo Single oral dose of placebo ascending doses HS-10356 multiple doses HS-10356 Multiple oral doses of HS-10356 ascending doses Placebo multiple doses Placebo Multiple oral doses of placebo ascending doses
- Primary Outcome Measures
Name Time Method Laboratory assessment:Haematology Predose, day4、day7、day10、day14、day19 prior to discharge from hospital in MAD Laboratory assessment:Clinical Chemistry Predose, day4、day7、day10、day14、day19 prior to discharge from hospital in MAD Laboratory assessment:Routine Urinalysis Predose, day4、day7、day10、day14、day19 prior to discharge from hospital in MAD Laboratory assessment:Coagulation test Predose, day4、day7、day10、day14、day19 prior to discharge from hospital in MAD Vital signs:Blood pressure Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD Vital signs:Pulse rate Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD Vital signs:Respiratory rate Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD Vital signs:Temperature Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14,once a day on days 15 to 19 in MAD Physical examination:Lymph node 24hours after the first and last administration, prior to discharge from hospital in MAD Physical examination:Chest 24hours after the first and last administration, prior to discharge from hospital in MAD Physical examination:Abdominal 24hours after the first and last administration, prior to discharge from hospital in MAD 12-lead electrocardiogram (ECG) parameters ( Heart rate, PR, R-R, QRS and QTcF (average)) Within 1 hour before administration,1hours, 2hours, 3hours, 24hours 120hours after administration in SAD. Physical examination:General 24hours after the first and last administration, prior to discharge from hospital in MAD The incidence, severity, and association of AE, SAE, and adverse events leading to withdrawal from the trial MAD: Day1~Day25
- Secondary Outcome Measures
Name Time Method SAD pharmacokinetic endpoint:Time to Cmax (Tmax) Day1-Day6 SAD pharmacokinetic endpoint:The maximum plasma concentration (Cmax) Day1-Day6 SAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC0-∞) Day1-Day6 SAD pharmacokinetic endpoint:Terminal rate constant (λz) Day1-Day6 SAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t) Day1-Day6 MAD pharmacokinetic endpoint:The minimum steady state drug concentration in plasma during dosing interval (Css,min) Day1-Day19 SAD pharmacokinetic endpoint:Half life (t½) Day1-Day6 SAD pharmacokinetic endpoint:Apparent clearance following extravascular administration (CL/F) Day1-Day6 SAD pharmacokinetic endpoint:Apparent volume of distribution following extravascular administration (Vd/F) Day1-Day6 SAD pharmacokinetic endpoint:Mean residence time (MRT) Day1-Day6 MAD pharmacokinetic endpoint:The maximum steady state drug concentration in plasma during dosing interval (Css,max) Day1-Day19 MAD pharmacokinetic endpoint:Average steady state drug concentration in plasma during dosing interval (Css,av) Day1-Day19 MAD pharmacokinetic endpoint:Time to Css, max (Tss,max) Day1-Day19 MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve over the dosing interval at steady state (AUCss) Day1-Day19 MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration at steady state(AUC0-t) Day1-Day19 MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC0-∞) at steady state Day1-Day19 MAD pharmacokinetic endpoint:Half life (t½) Day1-Day19 MAD pharmacokinetic endpoint:Accumulation ratio (Rac) Day1-Day19 MAD pharmacokinetic endpoint:Apparent clearance at steady state following extravascular administration (CLss/F) Day1-Day19 MAD pharmacokinetic endpoint:Apparent volume of distribution at steady state following extravascular administration (Vd/F) Day1-Day19
Trial Locations
- Locations (1)
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China